Additionally, pancreatic cancer data from Kaplan-Meier Plotter corroborate our findings, showing improved prognosis for patients with high VTN expression and better therapeutic outcomes when treated with anti-PD1 or anti-PD-L1. This evidence concerns the gene VTN and familial pancreatic carcinoma.